MinervaX ApS

About MinervaX ApS

MinervaX is a clinical-stage biotech company focused on developing a state-of-the-art prophylactic vaccine against Group B Streptococcus (GBS) to prevent adverse pregnancy outcomes and life-threatening infections in older people. Their mission is to make a global impact through innovative vaccine solutions.

Products & Services

AlpN GBS Vaccine:A lead vaccine candidate targeting Group B Streptococcus, currently in clinical testing for use in pregnant women and older adults to address unmet medical needs.

Specialties

Vaccine Development Group B Streptococcus (GBS) Prevention Clinical Trials for Pregnancy and Older Adults

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Venture Round T: - FT: Venture Round	A: 59400000 MR: - FA: EUR 54 million FAN: 59400000	D: 2023-10-11 FD: 2023-10-11	11 investors

Venture Round Latest

2023-10-11

$59.4M

11 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ralf Clemens

MD, PhD

G

Geert Leroux-Roels

Professor Emeritus

W

William Ripley Ballou

Senior Scientific Advisor

H

Heinz-Josef (Joe) Schmitt

Infectious Disease Paediatrician and Professor of Infectious Diseases and Vaccine Development

X

Xavier Sáez Llorens

MD, Professor of Pediatrics

C

Clement Lewin

Principal at CSL Vaccine Consulting

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

MinervaX ApS Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised